Real‐World Survival Outcomes of Venetoclax Combination Therapies in Acute Myeloid Leukemia: Impact of Minimal Residual Disease Status and Antifungal Prophylaxis
Mariarita Sciumè, Alessandro Bosi, Alfredo Marchetti, Fabio Serpenti, Pasquale De Roberto, Sonia Fabris, Francesco Versino, Elena Tagliaferri, Francesco Passamonti, Nicola Stefano Fracchiolla · 2026
Read Real‐World Survival Outcomes of Venetoclax Combination Therapies in Acute Myeloid Leukemia: Impact of Minimal Residual Disease Status and Antifungal Prophylaxis by Mariarita Sciumè, Alessandro Bosi, Alfredo Marchetti, Fabio Serpenti, Pasquale De Roberto, Sonia Fabris, Francesco Versino, Elena Tagliaferri, Francesco Passamonti, Nicola Stefano Fracchiolla (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13660767.txt.
Description
Mariarita Sciume and co-authors study a leukemia drug mix in daily practice in a 2026 paper. The drug blocks a survival protein in cancer cells and pairs with gentler agents. It is now standard for patients too frail for strong chemotherapy. Fungus prevention drugs clash with it, forcing dose cuts with no agreed target.
The series covered patients treated first line and after relapse at their center. Remission rates were higher in first line use than in relapsed disease. Patients reaching remission lived about the same span in both groups. A low daily dose paired with one fungus drug linked to much shorter survival in the analysis.
Catalog record
| CREATOR | Mariarita Sciumè, Alessandro Bosi, Alfredo Marchetti, Fabio Serpenti, Pasquale De Roberto, Sonia Fabris, Francesco Versino, Elena Tagliaferri, Francesco Passamonti, Nicola Stefano Fracchiolla |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 33 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |